| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 09/13/2006 | CN1274296C Method for producing water dispersible dry powders from poorly soluble compounds |
| 09/13/2006 | CN1274294C Novel cyclosporin analog microemulsion preconcentrates |
| 09/13/2006 | CN1274293C Ready-to-use paracetamol injection solutions containing propylene glycol as the only cosolvent |
| 09/12/2006 | US7105574 Composition of GAP DMORIE and colipids; adjuvant of cytofectin and neutral lipid such as a phosphatidylethanolamine provide elevation of antibody levels particularly in applications where antibody levels from the immunogen-encoding polynucleotide alone are sub-optimal |
| 09/12/2006 | US7105572 Cardiovascular disorders |
| 09/12/2006 | US7105571 Substituted aminoalkanoate or substituted aminoalkyl alkanoate as a penetration enhancer a shear-thinning polysaccharide, a lipophilic compound, and an acidic buffer system. |
| 09/12/2006 | US7105490 Methods and compositions for treating polycystic ovary syndrome |
| 09/12/2006 | US7105489 Methods and compositions for treating polycystic ovary syndrome |
| 09/12/2006 | US7105486 Administering L-lysine-d-amphetamine; attention deficit hyperactivity disorder; decreasing the bioavailability of amphetamine by intravenous or intranasal administration, further limiting their abuse liability. |
| 09/12/2006 | US7105482 Administering {(3R, 4S, 5S, 6R)-5-Methoxy-4-[(2R, 3R)-2-methyl-3-(3-methyl-but-2-enyl)-oxiranyl]-1-oxa-spiro[2.5]oct-6-yloxycarbonylamino}-3-methyl-butyric acid methyl ester; parasitic infections, thymoma, and lymphoid malignancies; prevents the metabolic degradation of the angiogenesis inhibitor |
| 09/12/2006 | US7105229 Dispersing a matrix of nanostructured liquid phase or a dehydrated variant and a nanostructured liquid crystalline phase or a dehydrated variant in nonlamellar material; cooling or evaporating a volatile solvent |
| 09/12/2006 | US7105180 Storage stability; bioavailability; core containing drug such as omeprazole, enteric overcoating |
| 09/12/2006 | US7105176 Dissolving or dispersing active compounds in aqueous or colloidal dispersion of a proteinaceous protecting colloid, flocculating with active compound out of dispersion separating off flocculated solid; forming dry powder |
| 09/12/2006 | US7105169 Cyanovirin conjugates and matrix-anchored cyanovirin and related compositions and methods of use |
| 09/12/2006 | US7105162 Peptide or protein from a pathogenic or tumor agent having immunomodulatory activity with an adjuvant capable of increasing the binding of the peptide to the cells of the individual or increasing the entry of the peptide into the cells; strengthening immunomodulatory activity; polyamino acids adjuvants |
| 09/12/2006 | US7105160 Antibody-serum protein hybrids |
| 09/12/2006 | US7105154 Orally administering interferon-tau to intestinal tract to produce measureable increase in patient's blood level of 2*,5*-oligoadenylate synthetase (OAS); autoimmune disease, viral infection and cancer treatment |
| 09/12/2006 | US7105153 Thickener-rheology modifier system for personal care compositions |
| 09/12/2006 | CA2375652C Film forming compositions comprising modified starches and iota-carrageenan and methods for manufacturing soft capsules using same |
| 09/12/2006 | CA2346539C Compositions and methods for enhancing receptor-mediated cellular internalization |
| 09/12/2006 | CA2315110C Pellets having a core coated with an antifungal and a polymer |
| 09/12/2006 | CA2312545C Solid, thermoformable, controlled-release pharmaceutical compound |
| 09/12/2006 | CA2307037C Oral pharmaceutical preparation comprising an antiulcer activity compound, and process for its production |
| 09/12/2006 | CA2298259C Basic drug compositions with enhanced bioavailability |
| 09/12/2006 | CA2240684C Aerosol preparation |
| 09/12/2006 | CA2195881C Stabilization of colloidal systems through the formation of lipid-polysaccharide complexes |
| 09/12/2006 | CA2194576C Long-acting oxytetracycline composition |
| 09/12/2006 | CA2183549C Acidified nitrite as an antimicrobial agent |
| 09/08/2006 | WO2006093969A2 Particles with high internal pressure for tissue ablation |
| 09/08/2006 | WO2006093390A1 Nonporous microspheres including drug and manufacturing method thereof |
| 09/08/2006 | WO2006093353A1 Release-control composition |
| 09/08/2006 | WO2006093222A1 Inhibitor for insulin polymer formation |
| 09/08/2006 | WO2006093139A1 Transdermally absorbable preparation |
| 09/08/2006 | WO2006093108A1 Gene transfer agent |
| 09/08/2006 | WO2006093066A1 Pressure-sensitive adhesive base and medical adhesive patch including the pressure-sensitive adhesive base |
| 09/08/2006 | WO2006092829A1 External plaster containing flurbiprofen |
| 09/08/2006 | WO2006092739A1 Anti-inflammatory conjugates of macrolides and coumarins |
| 09/08/2006 | WO2006092581A1 Lubricating composition |
| 09/08/2006 | WO2006092230A2 Protein-binding camptothecin peptide derivatives and medicaments comprising the same |
| 09/08/2006 | WO2006092229A1 Protein-binding anthracyclin peptide derivatives and medicaments comprising the same |
| 09/08/2006 | WO2006092209A1 Novel targets and compounds useful in the treatment of a cardiovascular disorder, dyslipidemia and atherosclerosis, and methods to identify such compounds |
| 09/08/2006 | WO2006092057A1 Amine-based and imine-based polymers, uses and preparation thereof |
| 09/08/2006 | WO2006081279A3 Control of drug release by transient modification of local microenvironments |
| 09/08/2006 | WO2006053882A3 Benzothiazole formulations and use thereof |
| 09/08/2006 | WO2006053006A3 Retinoid solutions and formulations made therefrom |
| 09/08/2006 | WO2006042847A3 Method for the preparation of oxime, thiazolidine, dithiane, dithiolane or hydrazone linked analogues of growth hormone |
| 09/08/2006 | WO2003086273A8 Histone conjugates and uses thereof |
| 09/08/2006 | CA2610343A1 Release-control composition |
| 09/08/2006 | CA2603139A1 Amine-based and imine-based polymers, uses and preparation thereof |
| 09/08/2006 | CA2599312A1 Process for the production of calcium compositions in a continuous fluid bed |
| 09/08/2006 | CA2598680A1 Particles |
| 09/07/2006 | US20060200213 Method and apparatus for skin treatment |
| 09/07/2006 | US20060199867 Ambroxol for the treatment of chronic pain |
| 09/07/2006 | US20060199863 Product containing prostaglandin |
| 09/07/2006 | US20060199861 Methods of using derivatives of (-)-venlafaxine |
| 09/07/2006 | US20060199860 Salts of (-)-O-desmethylvenlafaxine |
| 09/07/2006 | US20060199859 Topical medicaments and methods for photodynamic treatment of disease |
| 09/07/2006 | US20060199831 Injectable pharmaceutical compositions of an anthracenedione derivative with anti-tumoral activity |
| 09/07/2006 | US20060199793 Sterol absorption inhibitor compounds |
| 09/07/2006 | US20060199791 Personal hygiene and hard surface cleaning agent; acne, skin complaints; effective against antibiotic resistant bacteria |
| 09/07/2006 | US20060199787 N-(2-acetamidoethyl)phosphonoformamide; inhibiting effect on zinc-containing proteinases, inhibiting cancer cells |
| 09/07/2006 | US20060199782 Gene therapy using a SYN3 and SYN3 homolog delivery enhancing agent with an interferon protein or an interferon gene delivery system; anticarcinogenic agents |
| 09/07/2006 | US20060199778 Methods and products related to non-viral transfection |
| 09/07/2006 | US20060199777 Novel technology of intracellular delivery of dna oligonucleotides to improve drug activity |
| 09/07/2006 | US20060199770 Functionalized carbon nanotubes, a process for preparing the same and their use in medicinal chemistry |
| 09/07/2006 | US20060199763 Derivatives of GLP-1 analogs |
| 09/07/2006 | US20060199759 Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same |
| 09/07/2006 | US20060198898 Orally administering edible oil homogenized with an edible wax at a concentration ranging from 0.5% to 50% by weight and a sterol compound at a concentration of at least 0.1% by weight for repairing and promoting regeneration of mucosa in the GI tract |
| 09/07/2006 | US20060198892 Polymeric systems for controlled drug therapy |
| 09/07/2006 | US20060198880 Ultraviolet-shielding type patch |
| 09/07/2006 | US20060198879 An ionic medicine impregnated into an electrode-free ion-exchange membrane having a surface roughness (Rz) of 1 mu m or less; no application of voltage |
| 09/07/2006 | US20060198878 Preparation in film form for biphasic release of pharmaco-logically active or other substances |
| 09/07/2006 | US20060198873 Orally dissolving films |
| 09/07/2006 | US20060198872 Plant based dietary supplement for improving the duration and quality of sleep |
| 09/07/2006 | US20060198871 Methods for treating neovascularization and intravitreal implants |
| 09/07/2006 | US20060198850 Pharmaceutical formulation and a method of making same |
| 09/07/2006 | US20060198843 a cancer which expresses epidermal growth factor receptor; blocking ligand activation of a receptor; binding of monoclonal antibody 2C4 to ErbB2; chemotherapeutic agents are 5-fluorouracil leucovorin, levamisole |
| 09/07/2006 | US20060198840 increased in vivo half-lives due to the presence of an immunoglobulin G (IgG) constant domain; pharmacokinetics; diagnosis or immunotherapy; antibody conjugates; palivizumab |
| 09/07/2006 | US20060198833 Compositions and methods for targeting a polypeptide to the central nervous system |
| 09/07/2006 | US20060198823 Compositions and methods for treating viral infections |
| 09/07/2006 | US20060198820 Methods and compositions for treating secondary tissue damage and other inflammatory conditions and disorders |
| 09/07/2006 | US20060198817 Materials and methods for preventing and treating microbe-mediated epithelial disorders |
| 09/07/2006 | US20060198815 Pharmaceutical formulations for sustained release |
| 09/07/2006 | US20060198814 Preventing the intrusion of microorganisms into body cavities or body openings of mammals comprising of a poly(N-vinyl lactam), a polysaccharide and water; stable in a wide temperature range |
| 09/07/2006 | US20060196500 Closure-cap and container as a two-chamber cartridge for nebulisers for producing aerosols and active substance formulations, suitable for storage |
| 09/07/2006 | DE10015906B4 Gerichteter Gentransfer in Thy-1-positive Zellen Targeted gene transfer in Thy-1-positive cells |
| 09/06/2006 | EP1698640A1 Method of stabilizing antibody and stabilized solution-type antibody preparation |
| 09/06/2006 | EP1698629A2 Polyamines and their use in therapy |
| 09/06/2006 | EP1698349A1 Method of improving suitability for granulation |
| 09/06/2006 | EP1698330A1 Anti-inflammatory analgesic external preparation |
| 09/06/2006 | EP1698329A1 Drug-containing nanoparticle, process for producing the same and parenterally administered preparation from the nanoparticle |
| 09/06/2006 | EP1698328A2 Concentrate of Tocopherol |
| 09/06/2006 | EP1697511A2 Immunotherapy compositions, method of making and method of use thereof |
| 09/06/2006 | EP1697398A2 Aqueous suspensions of ciclesonide for nebulisation |
| 09/06/2006 | EP1697302A1 Compounds for diagnosis, treatment and prevention of bone injury and metabolic disorders |
| 09/06/2006 | EP1697050A2 Fiber rich fraction of trigonella foenum-graceumseeds and its use as a pharmaceutical excipient |
| 09/06/2006 | EP1696965A1 Assembly of gas-filled microvesicle with active component for contrast imaging |
| 09/06/2006 | EP1696963A2 Compositions and methods for the treatment of tumor of hematopoietic origin |
| 09/06/2006 | EP1696962A2 Novel glp-1 analogues linked to albumin-like agents |
| 09/06/2006 | EP1696961A1 Nanoparticle compositions of water-soluble drugs for oral administration and preparation methods thereof |